Propanc Biopharma, Inc.

PPCBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1517681

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Cost of Goods and Services Sold	—	—	—	—	—
Research and Development Expense	$248.1K	$247.9K	$256.1K	$231.0K	$180.0K
Operating Expenses	$1.5M	$1.8M	$2.0M	$1.8M	$3.5M
Operating Income (Loss)	-$1.5M	-$1.8M	-$2.0M	-$1.8M	-$3.5M
Interest Expense	—	—	$568.8K	$449.5K	$1.7M
Nonoperating Income (Expense)	-$413.6K	-$1.0M	-$722.2K	-$327.2K	-$1.4M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$1.9M	-$2.8M	-$2.7M	-$2.1M	-$4.9M
Income Tax Expense (Benefit)	-$129.1K	-$129.8K	-$55.0K	-$113.4K	-$134.7K
Net Income (Loss) Attributable to Parent	-$1.8M	-$2.7M	-$2.7M	-$2.0M	-$4.7M
Earnings Per Share, Basic	-$1.4K	-$1.80	-$49.23	-$0.80	—
Earnings Per Share, Diluted	-$1.4K	-$1.80	-$49.23	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$72.4K	$60.3K	$81.7K	$13.1K	$98.5K
Assets, Current	$25.4K	$19.0K	$15.0K	$6.6K	$69.0K
Cash and Cash Equivalents, at Carrying Value	—	—	—	$2.3K	$67.0K
Liabilities	$3.9M	$3.2M	$3.1M	$3.1M	$3.7M
Liabilities, Current	$3.8M	$3.2M	$3.1M	$3.1M	$3.7M
Long-term Debt	$399.3K	$390.5K	$926.4K	$624.6K	$1.6M
Accounts Payable, Current	$1.2M	$966.7K	$943.0K	$1.0M	$842.2K

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$935.1K	-$1.1M	-$1.4M	-$1.1M	-$1.8M
Net Cash Provided by (Used in) Investing Activities	—	—	—	—	—
Net Cash Provided by (Used in) Financing Activities	$941.9K	$1.1M	$1.5M	$1.1M	$1.9M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)